Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-25-006984
Filing Date
2025-01-27
Accepted
2025-01-27 16:05:15
Documents
17
Period of Report
2025-03-10

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT ea022803801-def14a_citius.htm   iXBRL DEF 14A 516106
2 GRAPHIC image_001.jpg GRAPHIC 86775
3 GRAPHIC image_002.jpg GRAPHIC 170533
4 GRAPHIC image_003.jpg GRAPHIC 292743
  Complete submission text file 0001213900-25-006984.txt   2642529

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ctxr-20250117.xsd EX-101.SCH 11035
6 XBRL DEFINITION FILE ctxr-20250117_def.xml EX-101.DEF 5394
7 XBRL LABEL FILE ctxr-20250117_lab.xml EX-101.LAB 36773
8 XBRL PRESENTATION FILE ctxr-20250117_pre.xml EX-101.PRE 7764
19 EXTRACTED XBRL INSTANCE DOCUMENT ea022803801-def14a_citius_htm.xml XML 206104
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-38174 | Film No.: 25559031
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)